2013 Archived Content

(SC18) Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts  

Overview of the requirements and processes for coordinated NDA/PMA or BLA/PMA submissions leading to simultaneous approvals of a therapeutic and companion diagnostic; from working with CDER, CBER and CDRH to labeling considerations, as well as an overview of the evolving Rx/Dx regulatory landscape.
Nancy Gerber, Associate Director, Regulatory Affairs, Genentech
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.
Pamela L. Swatkowski, Director, Regulatory Affairs, Abbott Molecular, Inc.
 

This course will cover:

  • Overview of US requirements and processes  
  • US government oversight of diagnostics
  • Diagnostic clearance and approval pathways
  • Predictive and prognostic diagnostics
  • Co-development process & timelines
  • Regulatory challenges   
  • FDA guidances and environment
  • Integration of Rx and Dx development plans
  • Navigating the development process
  • Co-development examples and lessons learned  
  • Historical examples (Erbitux, Vectibix)
  • Recent Scenarios (Xalkori, Zelboraf)
  • Approval path for devices ex-US
  • EU, Canada and Japan considerations

<<Back to Short Courses  

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 MMTC Final Agenda 

Premier Sponsors:

Abbott Molecular 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large 






Local Partners:

BayBio 


biocube 


Cabs 

City of SSF